GlassScriptPhysician profile
Amanda Rushing-Hiser
NPI 1124638192
$1,089.34
in general payments reported to CMS, 2019-2025
16 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $54.13 · 2023: $254 · 2024: $433 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $343.32 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $134.64 | 2022-2025 | Repatha, Otezla, Repatha |
| Penumbra, INC. | $131.18 | 2025 | Penumbra System |
| Medtronic, INC. | $117.30 | 2023-2025 | Endurant Iis, Intellis Adaptivestim, Vanta Adaptivestim |
| Exact Sciences Corporation | $64.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $61.76 | 2023-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.46 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $31.03 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Phathom Pharmaceuticals, INC. | $27.00 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $24.72 | 2023 | Inspire |
| Alnylam Pharmaceuticals INC. | $23.71 | 2023 | Givlaari |
| Sumitomo Pharma America, INC. | $23.21 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $21.93 | 2023 | |
| Pfizer INC. | $19.96 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.15 | 2023 | Breztri |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $15.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Rushing-Hiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.